Hopeful life to all,
through our developing
technology in the
regenerative medicine

We are seeking to establish new concept of regenerative medicine product,
hAP (holding Active Pharmaceutical ingredient) cell as combination of conventional pharmaceutical and living cell.
This is from our conviction that the regenerative medicine is not distinct
from conventional medicines, but rather can incorporate those to reach at next stage of therapy.

We are seeking to establish new concept of regenerative medicine product, hAP (holding Active Pharmaceutical ingredient) cell as combination of conventional pharmaceutical and living cell.
This is from our conviction that the regenerative medicine is not distinct from conventional medicines, but rather can incorporate those to reach at next stage of therapy.

Our Approach

Hopeful life to all, through our developing technology in the regenerative medicine

We are seeking to establish new concept of regenerative medicine product, hAP (holding Active Pharmaceutical ingredient) cell as combination of conventional pharmaceutical and living cell.

This is from our conviction that the regenerative medicine is not distinct from conventional medicines, but rather can incorporate those to reach at next stage of therapy.

Our Approach
NEWS RELEASE

Business

It is our duty to find good resolutions to accomplish your healthy lives for 100 years. For this goal, we are providing cost-effective and efficient new generation of regenerative medicine.

Our approach is completely different form existing pharmaceutical companies, keeping in mind “visiting old, learn new”.

再生医療製品開発事業

Regenerative medicine

Development of hAP cell, our original technology

CRO事業

CRO

Support of allover pharmaceutical affairs in Japan, especially to the regenerative medicine

M&A事業

M&A

Support of any alliances such as M&A in the area of medicine

New concept of “hAP cell”, as next stage of regenerative medicine

Drastic growth of regenerative medicine business is currently estimated to become up to 50 trillion yen in 2050.

However, already-approved regenerative medicine products have several problems such as “higher cost”, “lower efficiency” and “uneven qualities depending on the donners”, which are to be overcome to popularization.

Read more

Contact us

We also offer contract and co-development of hAP cells according to the client’s intentions.
We can help pharmaceutical companies to revive compounds that have been buried and dormant in their research and development for many years by using hAP cell technology.

If you are interested in this project, please feel free to contact us.
(Depending on the contents of your inquiry, we may have to sign a confidentiality agreement.)

We also offer contract and co-development of hAP cells according to the client’s intentions.
We can help pharmaceutical companies to revive compounds that have been buried and dormant in their research and development for many years by using hAP cell technology.

If you are interested in this project, please feel free to contact us.(Depending on the contents of your inquiry, we may have to sign a confidentiality agreement.)

Contact Us